Fierce Pharma January 2, 2024
In 2022, fueled by its powerhouse COVID products, Pfizer became the first company in the history of the biopharma industry to top $100 billion in annual revenue. What would the New York drugmaker do for an encore?
In 2023, Pfizer went from generating the most sales in the industry to gaining the most approvals.
With seven FDA nods in 2023, Pfizer had more than double that of any other company. It’s also more than twice as many as every drugmaker over each of the last three years. You need to go back to 2019, when Novartis scored six approvals, to find a company that approached what Pfizer accomplished in 2023.
Pfizer’s splurge included four approvals in a...
Today's Sponsors
Today's Sponsor